Skip to main content

Tweets

Schulz-Koops reports 2 #RA patients Rx with RTX who died from COVID pneumonia and ARDS. Both were older, had comorbidities (COPD, HTN, OP) and had received last RTX either 2 wks and 6 mos before COVID infection onset; both had nl IgG levels https://t.co/j043Tggdbg

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
Nested case-control study of 5858 SLE patients - 51 developed cancer; most common were thyroid CA (27%), cervical (20%), & lung (14%). No risk imposed by steroids, CTX, MTX or azathioprine. But HCQ use was associated significantly lower Cancer risk in SLE https://t.co/3R0iakKbVG

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
National Inpatient study of 61,615 systemic sclerosis pts (1998–2016) finds most common serious infections were pneumonia 45%, sepsis 32%, SSTI 19%; by 2015–2016, sepsis 1.8X more common than pneumonia. Hosp SIE mortality decr over time (10% to 8%) https://t.co/nv1KjaL3w4

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
According to the Agency for Healthcare Research & Quality, it is estimated that 40-80% of information a patient is told during an office visit is forgotten immediately, and that almost half of the information a patient does retain is actually incorrect https://t.co/XeGx2YXsOQ

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
2000–2016, analgesic use for OA has changed in UK. Oral NSAIDs Rx decreased & other analgesics/opioids increased (P < 0.001). Pts w/ GI dz likely to recv topical NSAIDs, tylenol, opioids. Opioids moreso in elderly, women, obesity, smokers, comorbidities. https://t.co/AJiWUAycLb

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
CHMP of the EMA has recommended approval of intravenous & subcutaneous formulations of CT-P13 (Remsima) for use in 5 conditions - Crohn, UC, ankylosing spondylitis, PsA & psoriasis. Remsima dose is 120 mg q 2wks regardless of body weight. https://t.co/eDUCvQost9

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
A must watch with volume on! It is so relatable. I might adopt the same response next time I get that question "But where are you from? shortly after I said Cheshire. Even though I wasn't born here, I think spending best half of my life here qualifies the answer. https://t.co/dVdgjQl7pU

Dr Yeliz Prior #BlackLivesMatter YelizPrior( View Tweet)

1 month 1 week ago
Increased rate of hospital #COVID-19 cases associated with some but not all chronic #inflammatory or #autoimmune conditions compared with reference population. The risks seem to depend on age, the specific disease and previous therapies. https://t.co/8j6R0oO99y https://t.co/n3cEXFx9Kk
ARD & RMD Open ARD_BMJ( View Tweet)
1 month 1 week ago
Now with ~1,000 children and adolescents with multi-inflammatory syndrome in children (MIS-C), it can be considered a new disease. Today new @NEJM reports and an editorial on its status. I've made a summary of some key points to start https://t.co/1HSWSvumpv
Eric Topol EricTopol( View Tweet)
1 month 1 week ago
The CHMP of the European Medicines Agency has recommended the label expansion of IL-17 inhibitor, Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years. https://t.co/1qYL5ASkrg

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
Fasinumab, nerve growth factor inhibitor, studied in a phase II trial of 421 moderate-to-severe OA (knee or hip) pts x36 wks & show to be better than placebo. But FAS had more AE (17% v 10%), Jt Surgeries (7% v 1%) and destructive arthropathy in 1 FAS pt https://t.co/eHvYrByF1Z

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
Truth does not belong to the one who shouts the loudest. https://t.co/QZWH5oHP6u

Dr. John Cush RheumNow( View Tweet)

1 month 1 week ago
×